2023 World Conference on Lung Cancer (Posters)-EP12.01. Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR+ NSCLC Patients: The Updated Results

EP12.01. Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR+ NSCLC Patients: The Updated Results - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to evaluate the efficacy and safety of aumolertinib as a first-line therapy for elderly patients with EGFR mutation-positive NSCLC. The study enrolled 86 patients aged 65 and above, with a median age of 66 years. The patients were treated with aumolertinib alone and were assessed for objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and disease control rate (DCR).<br /><br />The results showed that the ORR and DCR were 74.4% and 97.7%, respectively. The best response rate included complete response (3.5%), partial response (70.9%), stable disease (23.3%), and progressed disease (2.3%). There were no significant differences in ORR and DCR between patients aged 65 and above and those below 65 in all subgroups.<br /><br />The median PFS for all patients was 25 months, with no significant difference between the two age groups. The 2-year PFS rates were similar as well. Median OS was not reached.<br /><br />In terms of safety, around 50% of patients experienced at least one adverse event (AE), with the most common being blood creatine phosphokinase increase, rash, and diarrhea. The incidence of grade 3 AEs was low, and there were no significant differences in AEs between the two age groups.<br /><br />Based on these findings, the study concluded that aumolertinib as a first-line therapy showed excellent efficacy and safety in elderly patients with EGFR mutation-positive NSCLC. The results were comparable to those seen in younger patients. Therefore, aumolertinib should be considered as a preferable standard treatment for both elderly and younger NSCLC patients with EGFR mutations.

Asset Subtitle

Shencun Fang

Meta Tag

Speaker Shencun Fang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

aumolertinib

first-line therapy

elderly patients

EGFR mutation-positive NSCLC

objective response rate

progression-free survival

overall survival

disease control rate

adverse event

standard treatment